Cho-Spn Lifescience And Research Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-12-2024
- Paid Up Capital ₹ 0.25 M
as on 18-12-2024
- Company Age 34 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -19.27%
(FY 2022)
- Profit -24.50%
(FY 2022)
- Ebitda -1.49%
(FY 2022)
- Net Worth 3.22%
(FY 2022)
- Total Assets 2.64%
(FY 2022)
About Cho-Spn Lifescience And Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.25 M, as per Ministry of Corporate Affairs (MCA) records.
Kirti Shah, Samir Shah, and Keyur Shah serve as directors at the Company.
- CIN/LLPIN
U73100MH1990PTC058586
- Company No.
058586
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 1990
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cho-Spn Lifescience And Research?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samir Shah  | Director | 25-Jun-2004 | Current |
| Keyur Shah | Director | 21-Aug-2023 | Current |
| Kirti Shah | Director | 28-Feb-1991 | Current |
Financial Performance of Cho-Spn Lifescience And Research.
Cho-Spn Lifescience And Research Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 19.27% decrease. The company also saw a substantial fall in profitability, with a 24.5% decrease in profit. The company's net worth moved up by a moderate rise of 3.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cho-Spn Lifescience And Research?
Unlock access to Cho-Spn Lifescience And Research's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Oboi Laboratories Pvt LtdActive 39 years 5 monthsKirti Shah, Samir Shah and 1 more are mutual person
Ciron Drugs And Pharmaceuticals Private LimitedActive 34 years 6 monthsKirti Shah, Samir Shah and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cho-Spn Lifescience And Research?
Unlock and access historical data on people associated with Cho-Spn Lifescience And Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cho-Spn Lifescience And Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cho-Spn Lifescience And Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
